Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05108935 · ClinicalTrials.gov registry record · NA
Providing PrEP, Hepatitis C Treatment, and MOUD Through Telemedicine at Greensboro SSP
A NA study, sponsored by Duke University.
- Completed
- Registry status
- NA
- Development phase
- 17
- Enrollment target
NCT05108935 is a NA study that has completed, run by Duke University. The registered enrollment target is 17 participants.
The verdict
NCT05108935, a NA study, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- NA
- Development phase
- 17 participants
- Enrollment target
Study Summary
The purpose of this study is to provide medication for opioid use disorder (MOUD) with buprenorphine and naloxone, or bup/nx, pre-exposure prophylaxis (PrEP) for HIV prevention, and/or hepatitis C treatment for persons who inject opioids accessing syringe services programs (SSPs), as part of a comprehensive harm reduction program, and assess the acceptability and feasibility of using telemedicine to implement the program. The initial visit will be conducted in person or remotely via telemedicine given COVID-19 protocols at the SSP site in Greensboro, North Carolina (NC); follow-up visits will be conducted via telemedicine.
Interventions
- DRUG Truvada
- DRUG Mavyret
- DRUG Suboxone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2022-02-17 |
| Est. Completion | 2023-03-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05108935
The ClinicalTrials.gov registry entry for NCT05108935 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Truvada is the first listed.
NCT05108935 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05108935 about?
NCT05108935 is a clinical study titled "Providing PrEP, Hepatitis C Treatment, and MOUD Through Telemedicine at Greensboro SSP". The purpose of this study is to provide medication for opioid use disorder (MOUD) with buprenorphine and naloxone, or bup/nx, pre-exposure prophylaxis (PrEP) for HIV prevention, and/or hepatitis C treatment for persons who inject opioids accessing syringe services programs (SSPs), as part of a compr...
What is the current status of trial NCT05108935?
This trial is currently completed. It is a NA study. The enrollment target is 17 participants. The study started on 2022-02-17. Estimated completion is 2023-03-30.
What interventions are being tested in trial NCT05108935?
The interventions under investigation include: Truvada (DRUG), Mavyret (DRUG), Suboxone (DRUG).
Who is sponsoring clinical trial NCT05108935?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.